Biotechnology Journal:利用昆虫细胞可快速生产安全性更加的甲型H1N1流感疫苗



维也纳科学家在新一期《生物技术杂志》上发表研究论文称利用昆虫细胞生产甲型H1N1流感疫苗可以大大提高疫苗生产效率和安全性。研究人员仅用了10周就利用昆虫细胞生产出减毒性的病毒重组颗粒,并实验在老鼠身上。

现在疫苗生产通常使用鸡胚,这样生产疫苗的周期较长,而且存在很多安全风险,比如感染人和禽类都可致病的H5N1病毒。如果能大规模使用昆虫细胞作为载体生产疫苗那将提高我们对各种突发传染病的紧急应对能力,迅速生产出对应疫苗。(生物谷Bioon.com)

生物谷推荐原始出处:

Biotechnology Journal Volume 5 Issue 1, Pages 17 - 23

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice

Florian Krammer 1, Sabine Nakowitsch 2, Paul Messner 3, Dieter Palmberger 1, Boris Ferko 2, Reingard Grabherr, Dr. 1 *

1Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria
2Avir Green Hills Biotechnology AG, Vienna, Austria
3Department of Nanobiotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria

Recent outbreaks of influenza A highlight the importance of rapid and sufficient supply for pandemic and inter-pandemic vaccines. Classical manufacturing methods for influenza vaccines fail to satisfy this demand. Alternatively, cell culture-based production systems and virus-like particle (VLP)-based technologies have been established. We developed swine-origin pandemic H1N1 influenza VLPs consisting of hemagglutinin (A/California/04/2009) and matrix protein. Hemagglutinin and matrix protein were co-expressed in insect cells by the baculovirus expression system. VLPs were harvested from infection supernatants, purified and used for intraperitoneal immunization of BALB/c mice. Immunization induced high serum antibody titers against A/California/04/2009 as well as hemagglutination inhibiting antibodies. Additionally, we compared VLP production in two different insect cell lines, Sf9 and BTI-TN5B1-4 (High FiveTM). Taken together VLPs represent a potential strategy for the fight against new pandemic influenza viruses.




上一篇:病毒在环境卫生作业环境中的存活潜力及感染风险防控探讨
下一篇:新加坡发现从昆虫细胞里分离出来的基因治疗载